LCTX
Lineage Cell Therapeutics Inc
$1.32
0.01 (0.38%) Today
— up— down
Market Cap
$327M+46.7%
Revenue (TTM)
$15.03M-37.1%
Net Income (TTM)
$-69,230,610+53.5%
EPS (TTM)
-0.28+53.5%
Shares Out
249.30M
249.30MOpen
$1.33
$1.33Previous Close
$1.31
$1.31Day Range
$1.29 – $1.34
$1.29 – $1.3452-Week Range
$0.91 – $2.09
$0.91 – $2.09Beta
1.49
1.49Volume
369.87K
369.87KAvg Volume
1.44M
1.44MAnalyst Rating
Buy
BuyExchange
NYSE MKT LLC
NYSE MKT LLCAbout LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.
